BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 16516418)

  • 1. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats.
    Shin SC; Choi JS; Li X
    Int J Pharm; 2006 Apr; 313(1-2):144-9. PubMed ID: 16516418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
    Shin SC; Choi JS
    Anticancer Drugs; 2009 Aug; 20(7):584-8. PubMed ID: 19491656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by baicalein.
    Li C; Kim M; Choi H; Choi J
    Arch Pharm Res; 2011 Nov; 34(11):1965-72. PubMed ID: 22139696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced tamoxifen bioavailability after oral administration of tamoxifen in rats pretreated with naringin.
    Choi JS; Kang KW
    Arch Pharm Res; 2008 Dec; 31(12):1631-6. PubMed ID: 19099234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced bioavailability of tamoxifen and its metabolite 4-hydroxytamoxifen after oral administration with biochanin A (an isoflavone) in rats.
    Singh SP; Wahajuddin ; Raju KS; Ali MM; Kohli K; Jain GK
    Phytother Res; 2012 Feb; 26(2):303-7. PubMed ID: 22131128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin.
    Cho YA; Lee W; Choi JS
    Pharmazie; 2012 Feb; 67(2):124-30. PubMed ID: 22512082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rats.
    Piao Y; Shin SC; Choi JS
    Biopharm Drug Dispos; 2008 May; 29(4):245-9. PubMed ID: 18338336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of morin on the bioavailability of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
    Shin SC; Piao YJ; Choi JS
    In Vivo; 2008; 22(3):391-5. PubMed ID: 18610753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats.
    Li C; Li X; Choi JS
    Arch Pharm Res; 2009 Jan; 32(1):133-8. PubMed ID: 19183886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats.
    Kim CS; Choi SJ; Park CY; Li C; Choi JS
    Anticancer Res; 2010 Jan; 30(1):79-85. PubMed ID: 20150620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
    Li C; Lim SC; Kim J; Choi JS
    Eur J Drug Metab Pharmacokinet; 2011 Sep; 36(3):175-82. PubMed ID: 21442417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of quercetin on the pharmacokinetics of Etoposide after oral or intravenous administration of etoposide in rats.
    Li X; Choi JS
    Anticancer Res; 2009 Apr; 29(4):1411-5. PubMed ID: 19414395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.
    Choi JS; Piao YJ; Kang KW
    Arch Pharm Res; 2011 Apr; 34(4):607-13. PubMed ID: 21544726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin.
    Hong SP; Chang KS; Koh YY; Choi DH; Choi JS
    Arch Pharm Res; 2009 Oct; 32(10):1447-52. PubMed ID: 19898809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats.
    Choi JS; Shin SC
    Int J Pharm; 2005 Mar; 292(1-2):149-56. PubMed ID: 15725561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats.
    Li C; Lee MY; Choi JS
    Pharmazie; 2010 Jul; 65(7):510-4. PubMed ID: 20662320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin.
    Choi JS; Jo BW; Kim YC
    Eur J Pharm Biopharm; 2004 Mar; 57(2):313-8. PubMed ID: 15018990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.
    Kumar S; Kwei GY; Poon GK; Iliff SA; Wang Y; Chen Q; Franklin RB; Didolkar V; Wang RW; Yamazaki M; Chiu SH; Lin JH; Pearson PG; Baillie TA
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1161-71. PubMed ID: 12604693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of morin on the pharmacokinetics of nicardipine after oral and intravenous administration of nicardipine in rats.
    Piao YJ; Choi JS
    J Pharm Pharmacol; 2008 May; 60(5):625-9. PubMed ID: 18416939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid chromatography-mass spectrometry method for the quantification of tamoxifen and its metabolite 4-hydroxytamoxifen in rat plasma: application to interaction study with biochanin A (an isoflavone).
    Singh SP; Wahajuddin ; Ali MM; Kohli K; Jain GK
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Oct; 879(27):2845-51. PubMed ID: 21890435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.